BPC-157: study-reported regimens in syringe units

The regimens on this page

Every option in the dropdown comes from the study-reported dosing table on the BPC-157 profile. Each entry names the amount, route and schedule as the paper reported them, the population the paper enrolled, and the source. Nothing is averaged, generalised or extrapolated across studies.

• 10 mg of BPC-157 in 250 cc of normal saline infused over one hour on day 1, followed on day 2 by 20 mg of BPC-157 in 250 cc of normal saline infused over one hour — 2 healthy adults (a 58-year-old Asian male and a 68-year-old Caucasian female) in an IRB-approved pilot safety study at a private clinic in Florida (IV). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (2025). Pilot safety study only; efficacy was not assessed.
• Self-administered subcutaneous injection once daily for 90 days following arthroscopic rotator cuff repair — Patients undergoing arthroscopic rotator cuff repair in a randomized, double-blind, placebo-controlled Phase 1 pilot trial (planned enrollment 30) (SC). Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery (2026). Registration record, status not yet recruiting; no results reported. Registration states no dose amount.
• Subcutaneous injection once daily for 14 days, administered by trained study staff — Adults with MRI-confirmed acute grade II hamstring strain in a randomized, double-blind, placebo-controlled Phase 2 trial (planned enrollment 120) (SC). BPC 157 for Acute Hamstring Muscle Strain Repair (2026). Registration record, recruiting; no results reported. Registration states no dose amount.
• Oral tablets each containing 1 mg of BPC-157: single dose of 1, 3 or 6 tablets (Phase 1a); then 3 tablets every 8 hours during 2 weeks (Phase 1b) — 42 healthy volunteers, male or female, 18 to 35 years of age, single center (ORAL). PCO-02 - Safety and Pharmacokinetics Trial (2015). Phase 1 safety and pharmacokinetics registration; trial status listed as unknown and no results are posted.
• Two gummies daily over an 8-week period — 40 physically active adults consuming peptide gummies containing Body Protection Compound BPC-157 (ORAL). A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery (2026). Single-arm registration listed as completed; primary outcomes were hs-CRP and IL-6. No results reported in the record.

How the arithmetic works

Vial milligrams divided by water millilitres gives concentration. The study's amount divided by that concentration gives a volume, and a U-100 syringe reads 100 units per millilitre. The general reconstitution calculator does the same arithmetic for any amount you type.

Frequently asked questions